anastrozole has been researched along with Cancer of Prostate in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether tamoxifen or anastrozole prevents gynecomastia and breast pain caused by bicalutamide (150 mg) without compromising efficacy, safety, or sexual functioning." | 9.11 | Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. ( Battaglia, M; Bertaccini, A; Boccardo, F; Comeri, G; Conti, G; Di Tonno, P; Durand, F; Ferraris, V; Galassi, P; Macchiarella, A; Manganelli, A; Martorana, G; Montefiore, F; Muscas, G; Potenzoni, D; Rubagotti, A; Selvaggi, FP; Siragusa, A; Zattoni, F, 2005) |
| "A randomized, double-blind, placebo-controlled multicenter trial involving 107 men receiving bicalutamide ('Casodex') 150 mg/day therapy following radical therapy for prostate cancer assessed tamoxifen ('Nolvadex') 20 mg/day and anastrozole ('Arimidex') 1 mg/day for the prophylaxis and treatment of gynecomastia/breast pain." | 9.11 | Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. ( Gallo, J; Morris, T; Saltzstein, D; Sieber, P, 2005) |
| "A randomized multicenter (14 centers) trial was conducted in 114 men with prostate cancer to determine whether the antiestrogen tamoxifen ('Nolvadex') 20 mg or the aromatase inhibitor anastrozole ('Arimidex') 1 mg prevent gynecomastia and breast pain during treatment with the non-steroidal antiandrogen bicalutamide ('Casodex') 150 mg, without compromising efficacy, safety, or quality of life." | 9.11 | Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. ( Boccardo, F; Conti, G; Del Monaco, D; Manganelli, A; Potenzoni, D; Rubagotti, A, 2005) |
| "To determine whether tamoxifen or anastrozole prevents gynecomastia and breast pain caused by bicalutamide (150 mg) without compromising efficacy, safety, or sexual functioning." | 5.11 | Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. ( Battaglia, M; Bertaccini, A; Boccardo, F; Comeri, G; Conti, G; Di Tonno, P; Durand, F; Ferraris, V; Galassi, P; Macchiarella, A; Manganelli, A; Martorana, G; Montefiore, F; Muscas, G; Potenzoni, D; Rubagotti, A; Selvaggi, FP; Siragusa, A; Zattoni, F, 2005) |
| "A randomized, double-blind, placebo-controlled multicenter trial involving 107 men receiving bicalutamide ('Casodex') 150 mg/day therapy following radical therapy for prostate cancer assessed tamoxifen ('Nolvadex') 20 mg/day and anastrozole ('Arimidex') 1 mg/day for the prophylaxis and treatment of gynecomastia/breast pain." | 5.11 | Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. ( Gallo, J; Morris, T; Saltzstein, D; Sieber, P, 2005) |
| "A randomized multicenter (14 centers) trial was conducted in 114 men with prostate cancer to determine whether the antiestrogen tamoxifen ('Nolvadex') 20 mg or the aromatase inhibitor anastrozole ('Arimidex') 1 mg prevent gynecomastia and breast pain during treatment with the non-steroidal antiandrogen bicalutamide ('Casodex') 150 mg, without compromising efficacy, safety, or quality of life." | 5.11 | Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. ( Boccardo, F; Conti, G; Del Monaco, D; Manganelli, A; Potenzoni, D; Rubagotti, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Thomas, MP | 1 |
| Potter, BV | 1 |
| Ghadjar, P | 1 |
| Aebersold, DM | 1 |
| Albrecht, C | 1 |
| Böhmer, D | 1 |
| Flentje, M | 1 |
| Ganswindt, U | 1 |
| Höcht, S | 1 |
| Hölscher, T | 1 |
| Müller, AC | 1 |
| Niehoff, P | 1 |
| Pinkawa, M | 1 |
| Sedlmayer, F | 1 |
| Zips, D | 1 |
| Wiegel, T | 1 |
| Boccardo, F | 2 |
| Rubagotti, A | 2 |
| Battaglia, M | 1 |
| Di Tonno, P | 1 |
| Selvaggi, FP | 1 |
| Conti, G | 2 |
| Comeri, G | 1 |
| Bertaccini, A | 1 |
| Martorana, G | 1 |
| Galassi, P | 1 |
| Zattoni, F | 1 |
| Macchiarella, A | 1 |
| Siragusa, A | 1 |
| Muscas, G | 1 |
| Durand, F | 1 |
| Potenzoni, D | 2 |
| Manganelli, A | 2 |
| Ferraris, V | 1 |
| Montefiore, F | 1 |
| Saltzstein, D | 1 |
| Sieber, P | 1 |
| Morris, T | 1 |
| Gallo, J | 1 |
| Del Monaco, D | 1 |
| Thönnessen, D | 1 |
| Wenz, F | 1 |
| Negri-Cesi, P | 1 |
| Colciago, A | 1 |
| Poletti, A | 1 |
| Motta, M | 1 |
| Santen, RJ | 1 |
| Petroni, GR | 1 |
| Fisch, MJ | 1 |
| Myers, CE | 1 |
| Theodorescu, D | 1 |
| Cohen, RB | 1 |
1 review available for anastrozole and Cancer of Prostate
| Article | Year |
|---|---|
Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer.
Topics: Adenocarcinoma; Anastrozole; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormo | 2020 |
4 trials available for anastrozole and Cancer of Prostate
| Article | Year |
|---|---|
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Breast Diseases; Double-Blind Method; Gynecomastia; | 2005 |
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormon | 2005 |
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormona | 2005 |
Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme | 2001 |
3 other studies available for anastrozole and Cancer of Prostate
| Article | Year |
|---|---|
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Discovery; Endometriosi | 2015 |
Radiotherapeutic prophylaxis of gynecomastia.
Topics: Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gynecomastia; Humans; | 2005 |
5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Anastrozole; Androgens; Androstenedione; Aromatase; Aromatase | 1999 |